GO:0004454 ketohexokinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004454 ketohexokinase activity is the molecular function that catalyzes ATP-dependent phosphorylation of D-fructose to D-fructose 1-phosphate.
• Ketohexokinase (KHK) exists as two major splice variants, KHK-A and KHK-C, which differ in tissue distribution and catalytic efficiency.
• KHK-C is the dominant fructokinase in liver, intestine, and kidney, while KHK-A is more widely expressed and can also phosphorylate fructose, albeit less efficiently.
• Loss of KHK activity or knockdown of KHK expression alters fructose metabolism and can protect against fructose-induced hepatic steatosis and insulin resistance.
• KHK is a promising therapeutic target in metabolic dysfunction-associated steatotic liver disease (MASLD), insulin resistance, and fructose-driven cancers.
• CRISPR-based knockout, point-mutation, and knock-in models are essential tools for dissecting KHK isoform-specific functions and catalytic residues.
Description
Ketohexokinase activity (GO:0004454) is a molecular function defined as the catalysis of the reaction ATP + D-fructose = ADP + D-fructose 1-phosphate. This enzymatic step is the first committed step in fructose metabolism and is responsible for the rapid clearance of dietary fructose from the portal circulation. Unlike glucose, which is phosphorylated by hexokinases and glucokinase, fructose is primarily phosphorylated by ketohexokinase (KHK, also known as fructokinase) in the liver, intestine, and kidney. The product, fructose 1-phosphate, is then cleaved by aldolase B to dihydroxyacetone phosphate and glyceraldehyde, which enter glycolysis and lipogenesis. Because this initial phosphorylation is not feedback-inhibited, high fructose intake can lead to uncontrolled substrate flux, ATP depletion, and lipogenesis. Consequently, ketohexokinase activity is a central node linking dietary fructose to metabolic disease, and it has become a target for therapeutic intervention in conditions such as hepatic insulin resistance, steatohepatitis, and cancer.
ketohexokinase activity At A Glance
| GO ID | GO:0004454 |
|---|---|
| GO term | ketohexokinase activity |
| Ontology | molecular_function |
| Synonym | ATP:D-fructose 1-phosphotransferase activity; hepatic fructokinase activity; ketohexokinase (phosphorylating) |
| Major function | Catalysis of ATP-dependent phosphorylation of D-fructose to D-fructose 1-phosphate |
| Reaction | ATP + D-fructose = ADP + D-fructose 1-phosphate |
| Enzyme | Ketohexokinase (KHK), including splice variants KHK-A and KHK-C |
| Tissue distribution | Predominantly liver, intestine, and kidney; KHK-A is more ubiquitous |
| Pathological relevance | Fructose-induced hepatic steatosis, insulin resistance, and cancer metabolism |
What Is GO:0004454?
According to the Gene Ontology, GO:0004454 ketohexokinase activity is defined as the catalysis of the reaction: ATP + D-fructose = ADP + D-fructose 1-phosphate. This activity is also known as ATP:D-fructose 1-phosphotransferase activity, hepatic fructokinase activity, or ketohexokinase (phosphorylating). It belongs to the molecular_function ontology aspect and is mediated by the enzyme ketohexokinase (KHK), which transfers a phosphate group from ATP to the C1 hydroxyl of D-fructose.
Why Is ketohexokinase activity Important in Cell Biology?
Ketohexokinase activity is important because it initiates the metabolic fate of dietary fructose and directly influences hepatic lipid synthesis, insulin sensitivity, and energy homeostasis. Unlike glucose phosphorylation, fructose phosphorylation by KHK is not feedback-inhibited, allowing rapid and unregulated fructose uptake that can deplete ATP and generate excess lipogenic substrates. This unique kinetic property makes KHK a key driver of fructose-induced metabolic dysfunction, including hepatic steatosis, insulin resistance, and inflammation. Moreover, KHK isoforms have distinct roles in different tissues and cancers, making them attractive targets for precision therapeutics.
• KHK catalyzes the first committed step of fructose metabolism, controlling fructose clearance and downstream lipogenesis.
• KHK-C is the major fructokinase in liver and intestine, while KHK-A is more widely expressed and may have distinct functions.
• Loss of KHK activity protects against fructose-induced hepatic steatosis and insulin resistance in animal models.
• KHK-A can promote tumor growth in colorectal cancer by supporting fructose metabolism in tumor-associated macrophages.
• KHK is a therapeutic target for MASLD, insulin resistance, and fructose-driven cancers.
• Residues in the fructose-binding pocket are critical for KHK-A catalytic activity, offering targets for small-molecule inhibitors.
• KHK knockdown versus kinase inhibition can exert divergent effects on fructose metabolism, highlighting the need for precise experimental models.
• Dietary fructose improves intestinal cell survival and nutrient absorption, partly through KHK-dependent metabolism.
• KHK activity can be measured using radiolabeled fructose analogs such as 6-deoxy-6-[18F]fluoro-D-fructose.
• CRISPR-based models enable dissection of KHK isoform-specific and catalytic functions in vivo and in vitro.
Mechanism, Genes and Research Methods
Substrate Binding and Catalysis
In simple terms: KHK grabs fructose and attaches a phosphate group to it using ATP.
Ketohexokinase binds D-fructose in a specific pocket and transfers the gamma-phosphate of ATP to the C1 hydroxyl group, yielding D-fructose 1-phosphate and ADP. Structural and mutational studies have identified key residues in the fructose-binding pocket that are required for KHK-A activity, and mutations in these residues abolish or reduce catalysis. The reaction is not feedback-inhibited by downstream metabolites, allowing rapid fructose phosphorylation even when cellular ATP levels are low.
Isoform-Specific Functions
In simple terms: There are two main forms of KHK, and they behave differently in different tissues.
The KHK gene produces two major splice variants: KHK-A and KHK-C. KHK-C is the dominant isoform in liver, intestine, and kidney, where it has high affinity for fructose and drives efficient fructose metabolism. KHK-A is more widely expressed and has lower fructose affinity, but it can still phosphorylate fructose and may have additional roles in other tissues. Knockdown of KHK versus inhibition of its kinase activity can exert divergent effects on fructose metabolism, suggesting that isoform-specific functions and non-catalytic roles may exist.
Downstream Metabolic Flux
In simple terms: The product of KHK, fructose 1-phosphate, is broken down into smaller molecules that feed into fat synthesis.
Fructose 1-phosphate produced by KHK is cleaved by aldolase B into dihydroxyacetone phosphate and glyceraldehyde, which enter glycolysis and lipogenesis. This unregulated flux can lead to increased hepatic triglyceride synthesis, very-low-density lipoprotein secretion, and insulin resistance. In intestinal cells, KHK-dependent fructose metabolism supports cell survival and nutrient absorption, highlighting tissue-specific roles.
Regulation of KHK Expression and Activity
In simple terms: The amount and activity of KHK can change based on diet and hormones.
KHK expression is regulated by dietary fructose, hormones such as insulin and glucagon, and transcription factors including ChREBP and SREBP-1c. Fructose feeding increases KHK-C expression in the liver, creating a feed-forward loop that enhances fructose clearance and lipogenesis. In cancer cells, KHK-A expression can be upregulated and support tumor growth through metabolic reprogramming.
Kinetic Properties and Inhibitors
In simple terms: KHK works very fast and is not slowed down by its products, making it a good drug target.
KHK has a high catalytic efficiency and lacks feedback inhibition by fructose 1-phosphate or downstream metabolites. This property makes it an attractive target for small-molecule inhibitors that could reduce fructose flux without affecting glucose metabolism. Residues in the fructose-binding pocket are essential for KHK-A activity and represent potential sites for inhibitor design. Additionally, radiolabeled fructose analogs such as 6-deoxy-6-[18F]fluoro-D-fructose can be used to measure KHK activity in vivo.
Key Genes Involved in GO:0004454 ketohexokinase activity
The following genes and proteins are directly involved in ketohexokinase activity, its regulation, and downstream fructose metabolism.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KHK | Encodes ketohexokinase, the enzyme catalyzing GO:0004454 | Isoform-specific functions, catalytic residues, therapeutic targeting |
| ALDOB | Aldolase B cleaves fructose 1-phosphate downstream of KHK | Hereditary fructose intolerance, metabolic flux |
| HK2 | Hexokinase 2 can phosphorylate fructose in some tissues | Fructose sensing in tumor-associated macrophages |
| SLC2A5 | GLUT5 fructose transporter | Fructose uptake and KHK substrate availability |
| SLC2A2 | GLUT2 glucose/fructose transporter | Hepatic fructose uptake |
| ChREBP | Transcription factor regulating lipogenic genes including KHK | Fructose-induced lipogenesis |
| SREBP-1c | Transcription factor regulating lipogenesis | Insulin resistance and steatosis |
| ACACA | Acetyl-CoA carboxylase, lipogenesis | Downstream of KHK flux |
| FASN | Fatty acid synthase, lipogenesis | Downstream of KHK flux |
| TNF | Inflammatory cytokine | Fructose-induced inflammation |
| IL6 | Inflammatory cytokine | Fructose-induced inflammation |
| INS | Insulin | Regulates KHK expression and activity |
| GCG | Glucagon | Counter-regulates KHK expression |
| PPARA | Peroxisome proliferator-activated receptor alpha | Fatty acid oxidation, counteracts KHK-driven lipogenesis |
| CPT1A | Carnitine palmitoyltransferase 1A | Mitochondrial fatty acid oxidation |
| AKT | Insulin signaling kinase | Insulin resistance downstream of KHK |
| IRS1 | Insulin receptor substrate 1 | Insulin signaling |
| PKLR | Pyruvate kinase L/R | Glycolysis downstream of KHK |
How Is ketohexokinase activity Regulated?
Ketohexokinase activity is regulated at multiple levels. Transcriptionally, KHK-C expression in the liver is induced by fructose feeding through ChREBP and SREBP-1c, creating a feed-forward loop that enhances fructose clearance and lipogenesis. Hormonally, insulin increases KHK expression, while glucagon suppresses it, aligning fructose metabolism with fed and fasted states. Post-translationally, KHK activity can be modulated by phosphorylation and by interaction with other proteins, although the precise mechanisms remain under investigation. In cancer cells, KHK-A expression can be upregulated by oncogenic signals and supports tumor growth through metabolic reprogramming. Additionally, KHK activity is not feedback-inhibited by its product fructose 1-phosphate, making it a constitutively active enzyme that responds primarily to substrate availability.
ketohexokinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KHK | MASLD, insulin resistance, colorectal cancer | KHK knockout and point-mutation cell models |
| ALDOB | Hereditary fructose intolerance | ALDOB knockout hepatocytes |
| HK2 | Colorectal cancer | HK2 knockout tumor-associated macrophages |
| ChREBP | MASLD, lipogenesis | ChREBP knockout hepatocytes |
| SREBP-1c | Insulin resistance, steatosis | SREBP-1c overexpression models |
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Excessive ketohexokinase activity drives hepatic fructose metabolism, leading to ATP depletion, increased lipogenesis, and hepatic steatosis. Knockdown or inhibition of KHK protects against fructose-induced steatosis and insulin resistance in animal models. KHK is therefore a promising therapeutic target for MASLD and related metabolic disorders.
Insulin Resistance and Type 2 Diabetes
Fructose metabolism via KHK contributes to hepatic insulin resistance by promoting lipogenesis and inflammation. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling have been demonstrated, with fructose specifically impairing insulin sensitivity. Targeting KHK activity may improve insulin sensitivity in patients with type 2 diabetes.
Colorectal Cancer
Hexokinase 2 senses fructose in tumor-associated macrophages to promote colorectal cancer growth, and KHK-A can support fructose metabolism in cancer cells. KHK-A expression is associated with tumor progression and poor prognosis in some cancers, making it a potential target for cancer therapy.
Hereditary Fructose Intolerance
While hereditary fructose intolerance is caused by aldolase B deficiency, KHK activity is upstream and can influence the severity of fructose toxicity. Understanding KHK function is essential for interpreting fructose metabolism in this disorder.
From ketohexokinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does KHK-C drive hepatic steatosis? | KHK-C knockout mouse or hepatocyte cell line |
| Which residues are required for KHK-A catalysis? | KHK-A point-mutation knock-in cell lines |
| Can KHK inhibition improve insulin sensitivity? | KHK kinase-dead knock-in models |
| Does KHK-A support tumor growth? | KHK-A overexpression in cancer cell lines |
| How does fructose flux affect intestinal cells? | Intestinal organoids with KHK knockout |
| Can KHK activity be measured in vivo? | Radiolabeled fructose analog imaging |
How to Study the ketohexokinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | KHK catalytic rate | Validation of KHK mutants and inhibitors |
| CRISPR knockout screen | Genes required for fructose metabolism | Discovery of KHK-dependent pathways |
| RNA-seq | KHK isoform expression and lipogenic genes | Characterization of KHK models |
| Proteomics | Protein expression and signaling changes | Insulin signaling downstream of KHK |
| 13C-fructose tracing | Metabolic flux through KHK | Lipogenesis and glycolysis |
| Radiolabeled fructose imaging | KHK activity in vivo | Non-invasive metabolic imaging |
| Organoid culture | Intestinal fructose metabolism | KHK-dependent cell survival |
| Phosphoproteomics | Signaling changes | Insulin resistance mechanisms |
Enzymatic Activity Assays
Ketohexokinase activity can be measured using coupled enzymatic assays that monitor ADP production or fructose 1-phosphate formation. Radiolabeled fructose analogs such as 6-deoxy-6-[18F]fluoro-D-fructose enable non-invasive imaging of KHK activity in vivo. These assays are essential for validating CRISPR-generated KHK mutants and inhibitors.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes that modulate fructose metabolism and KHK activity. Pooled screens with fructose as the sole carbon source can enrich for KHK-dependent pathways. These approaches are powerful for discovering synthetic lethal interactions and resistance mechanisms.
Transcriptomics and Proteomics
RNA-seq and proteomics can quantify KHK isoform expression and downstream lipogenic gene programs in response to fructose. Phosphoproteomics can reveal signaling changes downstream of KHK activity, such as insulin signaling alterations. These methods are useful for characterizing KHK knockout or overexpression models.
Metabolic Flux Analysis
Stable isotope tracing with 13C-fructose can measure flux through KHK and downstream pathways such as lipogenesis and glycolysis. This method is critical for understanding how KHK activity affects metabolic rewiring in health and disease.
How CRISPR Can Be Used to Study GO:0004454 ketohexokinase activity
Knockout
CRISPR knockout of KHK in cell lines and animal models abolishes ketohexokinase activity, allowing researchers to study the consequences of fructose metabolism loss. KHK knockout hepatocytes show reduced lipogenesis and improved insulin sensitivity when challenged with fructose. Knockout models are also useful for identifying compensatory pathways and isoform-specific functions.
Point Mutation
Point mutations in the KHK fructose-binding pocket can selectively abolish catalytic activity without affecting protein stability. CRISPR-mediated point-mutation knock-in models are valuable for dissecting catalytic versus non-catalytic functions of KHK. Such models can also validate small-molecule inhibitor binding sites.
Knock-in
Knock-in of tagged KHK (e.g., FLAG or GFP) enables affinity purification and imaging of KHK in live cells. Knock-in of disease-associated KHK variants can model human metabolic disorders. These models are essential for understanding KHK localization and interactions.
Overexpression
Overexpression of KHK-A or KHK-C in cell lines can drive fructose-dependent lipogenesis and proliferation. Overexpression models are useful for studying KHK-driven cancer metabolism and identifying selective inhibitors. They also allow comparison of isoform-specific effects on downstream signaling.
How EDITGENE Supports ketohexokinase activity Research
Researchers studying ketohexokinase activity-related genes often need to determine whether a candidate gene is causally involved in fructose metabolism, metabolic disease, or cancer. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for ketohexokinase activity research.
Frequently Asked Questions About ketohexokinase activity
What is ketohexokinase activity?
Ketohexokinase activity (GO:0004454) is the enzymatic function that catalyzes the ATP-dependent phosphorylation of D-fructose to D-fructose 1-phosphate, the first step in fructose metabolism.
What genes are involved in ketohexokinase activity?
The primary gene is KHK, which encodes ketohexokinase. Other genes such as ALDOB, HK2, SLC2A5, and ChREBP are involved in fructose metabolism and regulation.
What is the difference between KHK-A and KHK-C?
KHK-A and KHK-C are splice variants of the KHK gene. KHK-C is the dominant isoform in liver, intestine, and kidney with high fructose affinity, while KHK-A is more widely expressed and has lower affinity.
How is ketohexokinase activity measured?
It can be measured using coupled enzymatic assays, radiolabeled fructose analogs, or metabolic flux analysis with 13C-fructose.
What diseases are associated with ketohexokinase activity?
Ketohexokinase activity is linked to MASLD, insulin resistance, type 2 diabetes, and colorectal cancer.
Can CRISPR be used to study ketohexokinase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect KHK function and fructose metabolism.
Why is KHK a drug target?
KHK is not feedback-inhibited and drives unregulated fructose flux, making it a promising target for metabolic disease and cancer therapies.
What is the reaction catalyzed by ketohexokinase?
ATP + D-fructose = ADP + D-fructose 1-phosphate.
Does fructose metabolism require insulin?
Fructose metabolism via KHK is insulin-independent for uptake, but insulin regulates KHK expression and downstream lipogenesis.
What are the synonyms for ketohexokinase activity?
Synonyms include ATP:D-fructose 1-phosphotransferase activity, hepatic fructokinase activity, and ketohexokinase (phosphorylating).
Conclusion
Ketohexokinase activity (GO:0004454) is a critical molecular function that initiates fructose metabolism and links dietary fructose to hepatic steatosis, insulin resistance, and cancer. The enzyme KHK, with its isoforms KHK-A and KHK-C, is a promising therapeutic target, and CRISPR-based models are essential for dissecting its isoform-specific and catalytic functions. Understanding the regulation and downstream effects of ketohexokinase activity will inform new strategies for metabolic disease and cancer treatment.
References
- 1. Park SH et al.. 2024. Knockdown of ketohexokinase versus inhibition of its kinase activity exert divergent effects on fructose metabolism.. JCI Insight 9(23) PMID: 39418102
- 2. Softic S et al.. 2020. Fructose and hepatic insulin resistance.. Crit Rev Clin Lab Sci 57(5):308-322 PMID: 31935149
- 3. Yan H et al.. 2024. Hexokinase 2 senses fructose in tumor-associated macrophages to promote colorectal cancer growth.. Cell Metab 36(11):2449-2467.e6 PMID: 39471815
- 4. Ferreira JC et al.. 2024. Residues in the fructose-binding pocket are required for ketohexokinase-A activity.. J Biol Chem 300(8):107538 PMID: 38971308
- 5. Taylor SR et al.. 2021. Dietary fructose improves intestinal cell survival and nutrient absorption.. Nature 597(7875):263-267 PMID: 34408323
- 6. Leung K. 2004. 6-Deoxy-6-[(18)F]fluoro-D-fructose.. PMID: 22049574
- 7. Softic S et al.. 2017. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling.. J Clin Invest 127(11):4059-4074 PMID: 28972537
- 8. Zhang H et al.. 2026. Ketohexokinase: A central mediator of fructose-associated pathogenesis and promising therapeutic target.. Pharmacol Res 230:108330 PMID: 42379433
